white pills

J.P. Morgan Very Positive on 3 Battered Specialty Pharmaceutical Stocks

Ever since the infamous Hillary Clinton tweet about pharmaceutical drug pricing, the biotech and specialty pharmaceutical stocks have taken a huge beating. In some cases, the markets have knocked valuations ...
Read Full Story »
clinical trials

Why Nymox Pharmaceutical Took Off

Nymox Pharmaceutical Corp. (NASDAQ: NYMX) shares made solid headway in Wednesday’s session on positive results from a cancer trial. The company announced results from its seven-year prospective placebo controlled double-blind ...
Read Full Story »
Pills and tablets

With Acquisitions, Will Impax Become the Next Great Generic Drug Seller?

Impax Laboratories Inc. (NASDAQ: IPXL) is about to step into a key role in the U.S. generic drug market. The company plans to take on a substantial portfolio of generic ...
Read Full Story »
blood cells

Global Blood Therapeutics Rises After Pricing Secondary Offering

Global Blood Therapeutics Inc. (NASDAQ: GBT) shares saw a handy gain in the premarket on Tuesday, despite the company pricing its secondary offering below its previous price level. This could be the ...
Read Full Story »

Selecta Biosciences Closes in on IPO

Selecta Biosciences has registered an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) in regards to its initial public offering (IPO). The company intends to price its ...
Read Full Story »
DNA molecules

Syros Pharmaceuticals Announces Potential Pricing for IPO

Syros Pharmaceuticals has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company expects to price its 4 million shares ...
Read Full Story »

How Inovio Pharma Is Joining the Fight Against the Zika Virus

Inovio Pharmaceuticals Inc. (NASDAQ: INO), in conjunction with GeneOne Life Science, is pioneering a new treatment for the Zika virus. In fact, early Monday morning the companies announced that they have ...
Read Full Story »
Female patient on gurney

Could This Be a Turning Point for Fate Therapeutics?

Shares of Fate Therapeutics Inc. (NASDAQ: FATE) saw a healthy gain early on Monday following a key U.S. Food and Drug Administration (FDA) approval. Looking at the stock performance in 2016, ...
Read Full Story »
Pills and tablets

Paratek Makes Milestone Movement in Late-Stage Trial

Paratek Pharmaceuticals Inc. (NASDAQ: PRTK) saw its shares take a solid jump early on Friday after the results from its late-stage trial were released. The company announced that the Phase ...
Read Full Story »
Two Dollars

Tonix Pharmaceuticals Prices Secondary Offering

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) slid in Thursday’s session after the company announced the pricing of its secondary offering. It priced 5 million shares at $2, with an ...
Read Full Story »
Medical interface

6 Biopharma Movers Making a Run on Wednesday

The broad markets appeared to be turning around in Wednesday’s session after posting losses in the past four sessions. One reason for this resurgence is a few biopharma companies making ...
Read Full Story »

Revance Therapeutics Drops on Missed Late Stage Results

Revance Therapeutics Inc. (NASDAQ: RVNC) hit a new 52-week low in Tuesday’s session following the release of its late stage trial results. The reported results were from its Realise 1 ...
Read Full Story »

Why Infinity Pharmaceuticals Crashed

Infinity Pharmaceuticals Inc. (NASDAQ: INFI) saw perhaps making the biggest drop in the market on Tuesday, with shares plummeting by over two-thirds following a clinical mid-stage trial update. Though the company ...
Read Full Story »
Pills and tablets

Pfizer and Shire Move on IBD License Agreement

Pfizer Inc. (NYSE: PFE) made waves early on Tuesday after the announcement of its newest licensing deal. Shire PLC (NASDAQ: SHPG) announced it has agreed to license global rights to all indications ...
Read Full Story »
Money and plant

Jefferies Has 3 Growth Stocks to Buy With Big Upside and Catalyst Potential

With the market looking decidedly overbought, the question for investors is which way makes sense to rotate to. As we have mentioned in the past, while it sounds good, going ...
Read Full Story »